Supraventricular tachycardia treatment
Download kB Előnézet Absztrakt kivonat idegen nyelven Cardiovascular diseases and in particular cardiac arrhythmias as ventricular fibrillation have a leading role in mortality in the developed supraventricular tachycardia treatment.
Accordingly, cardiac arrhythmias represent a major area of cardiovascular research. Drug therapy has traditionally been the major type of treatment for both ventricular and supraventricular arrhythmias.
Therefore, in order to develop new more effective agents with less proarrhythmic potency, it is important to understand the mechanism of action of antiarrhythmic drugs at the organ, tissue, cellular and also subcellular levels.
Based on the promising results of recent cellular pathophysiological and pharmacological investigations in the present PhD thesis, we have focused our research especially on pharmacological modulation of repolarizing potassium and sodium-calcium exchanger NCX currents as key elements in generating arrhythmias.
The aims of the present study were: a To analyse the contribution of different auxiliary proteins to the altered expression of genes for Kir2.
Selection of a lead NCX blocker compound for further analysis. Our results demonstrate: 1 The endogenous Kir2. In DCM, the levels magas vérnyomású erekkel Kir2.
These adaptations could offer a new aspect for the explanation supraventricular tachycardia treatment the generally observed physiological and molecular alterations found in DCM.
The SAP97 and Kir2. In addition, GYKB compound proved to be effective against DAD related arrhythmias, since in isolated Langendorff perfused heart experiments prevented disturbances of the heart rhythm in ouabain induced arrhythmias in guinea pigs.